Efficacy and Safety of Vibegron Add-On Therapy for Persistent Overactive Bladder Symptoms in Benign Prostatic Hyperplasia Patients With α1-Blocker Treatment: A Multi-Center Prospective Randomized Cont
3 hours ago
- #Benign Prostatic Hyperplasia
- #Vibegron
- #Overactive Bladder
- Study evaluates vibegron add-on therapy for persistent overactive bladder (OAB) symptoms in benign prostatic hyperplasia (BPH) patients on α1-blocker monotherapy.
- 158 patients were randomized to receive either vibegron add-on therapy or continue α1-blocker monotherapy for 12 weeks.
- Primary endpoint: Vibegron add-on therapy showed a significant improvement in OAB symptom score (OABSS) compared to monotherapy (difference: -1.4, p < 0.001).
- Secondary endpoints, including bladder diary parameters and patient satisfaction, favored vibegron add-on therapy.
- Vibegron was well-tolerated with no serious drug-related adverse events reported.
- Conclusion: Vibegron add-on therapy is effective and safe for BPH patients with persistent OAB symptoms.